Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial

BACKGROUND: Body weight loss (BWL) is a negative prognostic factor in metastatic gastric or gastroesophageal junction cancer (mGC/GEJC). In the phase III TAGS study, trifluridine/tipiracil improved survival versus placebo in third- or later-line mGC/GEJC. These retrospective analyses examined the as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghidini, Michele, Hochster, Howard, Doi, Toshihiko, Van Cutsem, Eric, Makris, Lukas, Takahashi, Osamu, Benhadji, Karim A., Mansoor, Wasat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284730/
https://www.ncbi.nlm.nih.gov/pubmed/37106214
http://dx.doi.org/10.1007/s10120-023-01393-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284730/
https://www.ncbi.nlm.nih.gov/pubmed/37106214
http://dx.doi.org/10.1007/s10120-023-01393-2

Ejemplares similares